ESR1 and breast carcinoma: A recent in vitro study showed abiraterone acted as an agonist in ER+ breast cancer cells and elicited ER-transcriptional activity.23 Such oestrogenic activity could impact on the effectiveness of abiraterone in the clinic given the proliferative response to oestrogen signalling by most ER+ breast cancer.